News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Advertise
Talent Solutions
Submit a Press Release
Submit an Event
SUBSCRIBE
Menu
SUBSCRIBE
Show Search
News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Advertise
Talent Solutions
Submit a Press Release
Submit an Event
Search Query
Submit Search
Search Results
Submit
Looking for jobs?
Search jobs
Close
743,265 Results
Type
Article (43861)
Company Profile (318)
Press Release (699072)
Multimedia
Podcasts (118)
Webinars (19)
Section
Business (211008)
Career Advice (2110)
Deals (36764)
Drug Delivery (127)
Drug Development (83431)
Employer Resources (176)
FDA (16838)
Job Trends (15505)
News (357418)
Policy (34138)
Tag
2027 BioMidwest Elite (1)
2027 Biotech Bay Standard (2)
2027 Biotech Beach Elite (1)
2027 Genetown Elite (3)
2027 Pharm Country Elite (1)
2027 Pharm Country Standard (3)
Academia (2618)
Accelerated approval (37)
Adcomms (26)
Allergies (155)
Alliances (51584)
ALS (179)
Alzheimer's disease (1704)
Antibody-drug conjugate (ADC) (338)
Approvals (17114)
Artificial intelligence (561)
Autoimmune disease (167)
Automation (44)
Bankruptcy (372)
Best Places to Work (11770)
BIOSECURE Act (21)
Biosimilars (200)
Biotechnology (188)
Bladder cancer (164)
Brain cancer (62)
Breast cancer (660)
Cancer (5026)
Cardiovascular disease (426)
Career advice (1790)
Career pathing (38)
CAR-T (289)
CDC (52)
Celiac Disease (2)
Cell therapy (770)
Cervical cancer (37)
Clinical research (71313)
Collaboration (1810)
Company closure (4)
Compensation (1192)
Complete response letters (66)
COVID-19 (2790)
CRISPR (101)
C-suite (908)
Cystic fibrosis (148)
Data (6464)
Decentralized trials (2)
Denatured (36)
Depression (139)
Diabetes (516)
Diagnostics (6824)
Digital health (49)
Diversity (12)
Diversity, equity & inclusion (45)
Drug discovery (269)
Drug pricing (205)
Drug shortages (31)
Duchenne muscular dystrophy (241)
Earnings (92201)
Editorial (61)
Employer branding (21)
Employer resources (155)
Events (120617)
Executive appointments (1017)
FDA (20072)
Fibrodysplasia Ossificans Progressiva (7)
Friedreich's ataxia (12)
Frontotemporal dementia (24)
Funding (1522)
Gene editing (210)
Generative AI (46)
Gene therapy (632)
GLP-1 (1026)
Government (4817)
Grass and pollen (7)
Guidances (386)
Healthcare (19074)
HIV (68)
Huntington's disease (48)
IgA nephropathy (86)
Immunology and inflammation (266)
Immuno-oncology (66)
Indications (128)
Infectious disease (3075)
Inflammatory bowel disease (204)
Inflation Reduction Act (14)
Influenza (123)
Intellectual property (263)
Interviews (327)
IPO (16923)
IRA (57)
Job creations (4070)
Job search strategy (1498)
JPM (64)
Kidney cancer (18)
Labor market (87)
Layoffs (576)
Leadership (35)
Legal (8425)
Liver cancer (93)
Longevity (18)
Lung cancer (676)
Lymphoma (387)
Machine learning (46)
Management (60)
Manufacturing (852)
MASH (172)
Medical device (13879)
Medtech (13939)
Mergers & acquisitions (20931)
Metabolic disorders (1329)
mRNA (171)
Multiple sclerosis (166)
NASH (17)
Neurodegenerative disease (337)
Neuropsychiatric disorders (93)
Neuroscience (3005)
Neurotech (1)
NextGen: Class of 2026 (6645)
Non-profit (4564)
Now hiring (69)
Obesity (629)
Opinion (292)
Ovarian cancer (169)
Pain (223)
Pancreatic cancer (239)
Parkinson's disease (292)
Partnered (34)
Patents (523)
Patient recruitment (523)
Peanut (62)
People (61003)
Pharmaceutical (90)
Pharmacy benefit managers (32)
Phase 1 (22137)
Phase 2 (31354)
Phase 3 (23497)
Pipeline (5820)
Policy (309)
Postmarket research (2655)
Preclinical (9402)
Press Release (68)
Prostate cancer (255)
Psychedelics (50)
Radiopharmaceuticals (296)
Rare diseases (912)
Real estate (6307)
Recruiting (72)
Regulatory (25529)
Reports (53)
Research institute (2445)
Resumes & cover letters (362)
Rett syndrome (29)
RNA editing (17)
RSV (81)
Schizophrenia (159)
Series A (255)
Series B (195)
Service/supplier (11)
Sickle cell disease (104)
Special edition (25)
Spinal muscular atrophy (161)
Sponsored (43)
Startups (3768)
State (2)
Stomach cancer (19)
Supply chain (108)
Tariffs (96)
The Weekly (80)
Vaccines (1048)
Venture capital (91)
Weight loss (413)
Women's health (99)
Worklife (19)
Date
Today (3)
Last 7 days (884)
Last 30 days (2731)
Last 365 days (30298)
2026 (4926)
2025 (30679)
2024 (35767)
2023 (40629)
2022 (51798)
2021 (56329)
2020 (54791)
2019 (47397)
2018 (35770)
2017 (33140)
2016 (32662)
2015 (38615)
2014 (32516)
2013 (27630)
2012 (29729)
2011 (30487)
2010 (28497)
Location
Africa (800)
Alabama (86)
Alaska (7)
Arizona (322)
Arkansas (15)
Asia (42202)
Australia (6760)
California (11681)
Canada (3377)
China (1159)
Colorado (491)
Connecticut (492)
Delaware (346)
Europe (90566)
Florida (1753)
Georgia (370)
Hawaii (3)
Idaho (61)
Illinois (904)
India (73)
Indiana (546)
Iowa (22)
Japan (454)
Kansas (127)
Kentucky (42)
Louisiana (27)
Maine (72)
Maryland (1423)
Massachusetts (8387)
Michigan (338)
Minnesota (639)
Mississippi (6)
Missouri (129)
Montana (32)
Nebraska (29)
Nevada (126)
New Hampshire (80)
New Jersey (3103)
New Mexico (29)
New York (3077)
North Carolina (1509)
North Dakota (8)
Northern California (5726)
Ohio (348)
Oklahoma (22)
Oregon (46)
Pennsylvania (2361)
Puerto Rico (24)
Rhode Island (49)
South America (1175)
South Carolina (69)
South Dakota (1)
Southern California (4559)
Tennessee (179)
Texas (1801)
United States (41449)
Utah (353)
Vermont (1)
Virginia (286)
Washington D.C. (81)
Washington State (947)
West Virginia (4)
Wisconsin (118)
Wyoming (2)
743,265 Results for "paratek pharmaceuticals inc".
Filters
Sort By
Relevance
Relevance
Newest
Oldest
Press Releases
Paratek Pharmaceuticals Announces Positive Results for NUZYRA® Therapeutic Efficacy Studies in Inhalation Anthrax Triggering Additional Procurement under BARDA Project BioShield Contract
February 24, 2026
·
6 min read
Press Releases
Paratek Pharmaceuticals to Present New Data on NUZYRA® (omadacycline) at IDWeek 2025 and CHEST 2025
October 20, 2025
·
11 min read
Mergers & acquisitions
Paratek Broadens Portfolio With OptiNose Buy Worth up to $330M
Paratek Pharmaceuticals is betting that OptiNose’s chronic rhinosinusitis treatment will be a partner to its antibiotic treatment Nuzyra.
March 20, 2025
·
1 min read
·
Dan Samorodnitsky
Press Releases
Paratek Pharmaceuticals Completes Acquisition of Optinose, Creating an Expanded Portfolio of Specialty Therapies
May 21, 2025
·
10 min read
Press Releases
Paratek Pharmaceuticals to Present New Data on NUZYRA® (omadacycline) at ESCMID Global 2025
April 10, 2025
·
6 min read
Press Releases
Paratek Pharmaceuticals to Present Clinical Data on NUZYRA® (omadacycline) at the American Thoracic Society (ATS) 2025 International Conference
May 16, 2025
·
6 min read
Press Releases
Paratek Pharmaceuticals to Acquire Optinose, Creating Significant Commercial Expansion Opportunities for XHANCE® in Chronic Rhinosinusitis (CRS)
March 20, 2025
·
17 min read
Business
Paratek Pharmaceuticals Announces Promotion of Jonathan Light to General Counsel, Corporate Secretary and Chief Compliance Officer and Christopher Bostrom to Chief Financial Officer
Paratek Pharmaceuticals, Inc. announced two key executive team promotions.
January 16, 2024
·
3 min read
Genetown
Paratek Pharmaceuticals Announces Inclusion of Oral NUZYRA® in China’s National Reimbursement Drug List
Paratek Pharmaceuticals, Inc. today announced that China’s National Healthcare Security Administration (NHSA) has added the oral formulation of NUZYRA® (omadacycline) to the country’s National Reimbursement Drug List (NRDL) for treatment of community-acquired bacterial pneumonia.
December 13, 2023
·
2 min read
Genetown
Paratek Pharmaceuticals to Present NUZYRA Data at IDWeek 2023
Paratek Pharmaceuticals, Inc. today announces that new data from NUZYRA ® (omadacycline) scientific and investigator-initiated research programs will be presented at IDWeek 2023.
October 5, 2023
·
3 min read
1 of 74,327
Next
